ライフサイエンスコーパス: angiotensin II receptor

1 overexpress individual GRKs and the type 1A angiotensin II receptor.

2 y to nerves and myocytes, which both express angiotensin II receptors.

3 RGS5 modulates signaling through the angiotensin II receptor 1 and major Galphaq-coupled down

4 a key intermediate for accessing a class of angiotensin II receptor 1 antagonists.

5 coding for components of the RAS (ACE gene, Angiotensin II receptor 1 gene, Angiotensinogen gene) in

6 tment of diabetic ZDF rats with losartan, an angiotensin II receptor-1 (Agtr1) antagonist, attenuated

7 nals TGF-beta1, CCN2 and ET-1, downstream of angiotensin-II-receptor-1 inhibition.

8 damage, and suppression of cardio-reparative Angiotensin II receptor 2 (Agtr2).

9 Angiotensin II receptor activation may result in angioge

10 The angiotensin II receptor AGTR1, which mediates vasoconstr

11 nd differentiation via signaling through the angiotensin II receptors AGTR1 and AGTR2.

12 osome 3q in a region encompassing the type 1 angiotensin II receptor (AGTR1) gene.

13 receiving regimens that inhibit type 2 and 4 angiotensin II receptors and 2.7 cases per 100 person-ye

14 tate optimal export trafficking of different angiotensin II receptors and export ability of each acid

15 The regulation of angiotensin II receptors and the two major subtypes (AT1

16 gical responses, contain the final effector (angiotensin II receptor), and respond to humoral, neural

17 tion to diabetic nephropathy; and renin, the angiotensin II receptor, and kallikrein because of their

18 armacologic agents that directly inhibit the angiotensin II receptor (angiotensin receptor blocker [A

19 Postburn administration of the angiotensin II receptor antagonist DuP753 significantly

20 e-blind treatment with eplerenone 50 mg, the angiotensin II receptor antagonist losartan 50 mg, or pl

21 sted whether losartan--a clinically approved angiotensin II receptor antagonist with noted antifibrot

22 Luminal 10(-8) M Dup 753 (an angiotensin II receptor antagonist) resulted in a 35% de

23 J6, we identified telmisartan, a widely used angiotensin II receptor antagonist, as a potent inhibito

24 ravitreal injection of saralasin, a specific angiotensin II receptor antagonist, had no significant e

25 12-week oral administration of losartan, an angiotensin II receptor antagonist, in patients with hea

26 o-OSA), all patients began treatment with an angiotensin II receptor antagonist, losartan, 50 mg dail

27 Losartan is a specific, nonpeptide angiotensin II receptor antagonist.

28 We assessed the role of the angiotensin-II-receptor antagonist losartan in patients

29 nsin-converting enzyme inhibitors (ACEI) and angiotensin II receptor antagonists (AT1RA) slow the rat

30 ceutical compounds such as renin inhibitors, angiotensin II receptor antagonists and aldosterone anta

31 angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists in the treatment of

32 hiazides, beta-blockers, ACE inhibitors, and angiotensin II receptor antagonists) in fixed doses in w

33 eroidal anti-inflammatories, loop diuretics, angiotensin II receptor antagonists, and beta-lactam ant

34 GPCRs, such as beta-adrenergic receptor and angiotensin II receptor antagonists.

35 Limited long-term data are available for the angiotensin II receptor antagonists.

36 Angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists are recommended for

37 angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney di

38 ACE inhibition and/or blocking of the angiotensin II receptor are recognized as first-line tre

39 tes blood pressure mainly through the type 1 angiotensin II receptor AT(1) R and its downstream signa

40 This hypertension is abolished by selective angiotensin II receptor AT-1 antagonist at a low dose th

41 a competitive receptor antagonist of type I angiotensin II receptors at a dose that would block cent

42 a) and interleukin-1 beta up-regulate type 1 angiotensin II receptor (AT(1)) mRNA and protein in cult

43 angiotensin-converting enzyme 2, the type 2 angiotensin II receptor (AT(2)R), the proto-oncogene Mas

44 Although 2 types of angiotensin II receptors (AT(1) and AT(2)) are upregulat

45 G protein-coupled angiotensin II receptors, AT(1)R and AT(2)R, are integra

46 andesartan, an inverse agonist of the type 1 angiotensin II receptor (AT1 R), causes a concentration-

47 d by losartan, the first of the new class of angiotensin II receptor (AT1) antagonists.

48 Activation of the type 1 angiotensin II receptor (AT1) triggers proinflammatory s

49 ion of the seven-transmembrane domain type 1 angiotensin II receptor (AT1-R) but it also suppresses e

50 e effects of cAMP-elevating agents on type I angiotensin II receptor (AT1-R) mRNA levels were assesse

51 onist-induced desensitization of the type 1A angiotensin II receptor (AT1A-R), we have stably express

52 The type 1A angiotensin II receptor (AT1A-R), which mediates cardiov

53 The angiotensin II receptors AT1R and AT2R serve as key comp

54 Losartan, a type I angiotensin II receptor (AT1R) antagonist, has been prev

55 Type I angiotensin II receptors (AT1R) are somewhat unique in t

56 pixel units (apu); P < 0.03), and increased angiotensin II receptor AT2 expression in the renal medu

57 drugs, the safety and beneficial effects of angiotensin II receptor blockade (ARB) in patients with

58 Brooke et al. now report that combining angiotensin II receptor blockade by losartan with beta-b

59 The clinical effects of long-term angiotensin II receptor blockade compared with ACE inhib

60 iotensin-converting enzyme inhibition versus angiotensin II receptor blockade on survival in rats wit

61 in fear extinction and the promise of using angiotensin II receptor blockade to reduce PTSD symptom

62 angiotensin-converting enzyme inhibitors or angiotensin II receptor blockade use (OR, 0.42; [95% CI,

63 and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockade use remained independen

64 ignificant difference between survival after angiotensin II receptor blockade with losartan and with

65 To determine whether specific angiotensin II receptor blockade with losartan offers sa

66 and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockade, were associated with t

67 Neither angiotensin II receptors blockade nor alpha and beta adr

68 , an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (ACE-I/ARB), and lipid-l

69 of trials have tested the hypothesis that an angiotensin II receptor blocker (ARB) could be as effect

70 In contrast, an angiotensin II receptor blocker (ARB) had no effect.

71 nsin converting enzyme inhibitor (ACEI), and angiotensin II receptor blocker (ARB) prescription at di

72 tensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) prescription, low-

73 he association of statin, ACE inhibitor, and angiotensin II receptor blocker (ARB) use with pneumonia

74 tensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB), and diuretic medi

75 giotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB), angiotensin recep

76 ensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB), statin, and nephr

77 vasodilating beta blocker (nebivolol) and an angiotensin II receptor blocker (valsartan) in adults wi

78 tensin-converting enzyme inhibitor [ACEi] or angiotensin II receptor blocker [ARB], prescription for

79 rs, whereas angiotensin-converting enzyme or angiotensin II receptor blocker adherence was not associ

80 the use of converting enzyme inhibitors and angiotensin II receptor blocker emphasizing doses, effic

81 laboratory monitoring after ACE inhibitor or angiotensin II receptor blocker initiation was not assoc

82 ted to assess the efficacy and safety of the angiotensin II receptor blocker irbesartan in adults wit

83 We aimed to assess the effect of the angiotensin II receptor blocker losartan on left ventric

84 shock and chronic hypertension treated with angiotensin II receptor blocker may benefit from a high

85 ut more expensive, heart failure medication (angiotensin II receptor blocker neprilysin inhibitor).

86 n angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker or angiotensin receptor-

87 of either angiotensin-converting enzyme plus angiotensin II receptor blocker or angiotensin-convertin

88 (angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker prescription for albumin

89 Treatment with the angiotensin II receptor blocker telmisartan improved glu

90 e synthesis of bioisosteric analogues of the angiotensin II receptor blocker telmisartan.

91 f angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker therapy and glucose-lowe

92 51 matched pairs initiating ACE inhibitor or angiotensin II receptor blocker therapy between January

93 as provided new information into the role of angiotensin II receptor blocker therapy in patients who

94 Angiotensin II receptor blocker therapy may be protectiv

95 Angiotensin II receptor blocker therapy was associated w

96 the 30 days after starting ACE inhibitor or angiotensin II receptor blocker therapy were matched 1:1

97 (angiotensin-converting enzyme) inhibitor or angiotensin II receptor blocker therapy.

98 o angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment, is a potentia

99 ons, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use, smoking cessation;

100 angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use, statin use (72.6% f

101 d angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use.

102 hly mean rate of 100 adverse events for 1000 angiotensin II receptor blocker users before and after g

103 nd, parallel, randomized controlled trial of angiotensin II receptor blocker valsartan 160 mg twice d

104 ial to assess the safety and efficacy of the angiotensin II receptor blocker valsartan in attenuating

105 parative data on the long-term effects of an angiotensin II receptor blocker versus an angiotensin-co

106 n angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker were newly prescribed H-

107 [angiotensin-converting enzyme] inhibitor or angiotensin II receptor blocker) and a newer, but more e

108 otensin-converting enzyme inhibitor) or ARB (angiotensin II receptor blocker), be switched to sacubit

109 ibitors, sparsentan (a dual endothelin-1 and angiotensin II receptor blocker), nefecon (a targeted re

110 ly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 weeks (primary en

111 Losartan, an angiotensin II receptor blocker, has been proposed as a

112 in converting enzyme blocker, lisinopril, or angiotensin II receptor blocker, losartan, did not impro

113 imed to determine the effect of losartan, an angiotensin II receptor blocker, on subpulmonary RV dysf

114 enalapril, an ACE inhibitor, or L-158809, an angiotensin II receptor blocker.

115 n angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.

116 the angiotensin II receptor, or losartan, an angiotensin II receptor blocker.

117 lass, lower diastolic blood pressure, and no angiotensin II receptor blocker/angiotensin-converting e

118 , angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker: 29.6% [95% CI, 25.7%-33

119 tensin converting enzyme inhibitor (ACEi) or angiotensin II-receptor blocker (ARB) use for those with

120 otensin-converting-enzyme (ACE) inhibitor or angiotensin II-receptor blocker (ARB).

121 inhibitor (moderate-quality evidence) or an angiotensin II-receptor blocker (high-quality evidence)

122 and early nephropathy to receive either the angiotensin II-receptor blocker telmisartan (80 mg daily

123 ngiotensin-converting enzyme inhibitor or an angiotensin II-receptor blocker.

124 The cardiovascular and renal outcomes of angiotensin-II receptor blocker (ARB) and angiotensin-co

125 The angiotensin-II-receptor blocker irbesartan is effective

126 It is unknown whether either the angiotensin-II-receptor blocker irbesartan or the calciu

127 angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (84.2%), and mineraloco

128 ensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) during hospitaliz

129 in II converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) presumably stimul

130 giotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARB), beta-blockers an

131 nsin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB).

132 nsin-converting enzyme inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) after AKI is unc

133 iotensin-converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers (ARBs) at discharge and

134 ensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) does not increas

135 ensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) for lowering blo

136 nsin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) have a positive,

137 otensin-converting enzyme inhibitors (ACEis)/angiotensin II receptor blockers (ARBs) in 57.4%, and mi

138 ensin-converting enzyme (ACEs) inhibitors or angiotensin II receptor blockers (ARBs) in CKD is lackin

139 ensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) inhibit the reni

140 ensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), more effectivel

141 sin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs).

142 oV-2 positive test result compared to use of angiotensin II receptor blockers (OR = 0.70, 95% CI 0.54

143 yme inhibitors (RR 0.84 [95% 0.76-0.93]) and angiotensin II receptor blockers (RR 0.84 [0.76-0.92]) r

144 angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers after AKI is uncertain.

145 Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and aldosterone antagon

146 EPHESUS have added insight into the role of angiotensin II receptor blockers and aldosterone in the

147 significant differences in adherence between angiotensin II receptor blockers and angiotensin-convert

148 s and beta-blockers and highest adherence to angiotensin II receptor blockers and angiotensin-convert

149 de angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and sodium-glucose co-t

150 Angiotensin II receptor blockers are beneficial in patie

151 dies of neutral endopeptidase inhibitors and angiotensin II receptor blockers are described.

152 We evaluated the impact of 3 generic angiotensin II receptor blockers commercialization on ad

153 There was better adherence to angiotensin II receptor blockers compared with angiotens

154 Patients with pre-ICU exposure to angiotensin II receptor blockers had significantly less

155 angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers having the most favoura

156 New users of ACEIs or angiotensin II receptor blockers in Denmark from January

157 The role of angiotensin II receptor blockers in patients with a syst

158 l studies are needed to assess the effect of angiotensin II receptor blockers in preclinical hypertro

159 e studies suggest that ACE inhibitors and/or angiotensin II receptor blockers may be effective treatm

160 Attenuation of TGF-beta signaling by angiotensin II receptor blockers may represent a mechani

161 sed case-control study indicates that use of angiotensin II receptor blockers might be associated wit

162 only if GFR decreases sufficiently, and that angiotensin II receptor blockers mitigate urinary albumi

163 studies have suggested beneficial effects of angiotensin II receptor blockers on left ventricular hyp

164 The effect of angiotensin II receptor blockers on right ventricular (R

165 d mitral valves and we tested the effects of angiotensin II receptor blockers on TGF-beta signaling i

166 dings challenge the generally held view that angiotensin II receptor blockers reduce cardiac hypertro

167 reatitis and 61,637 controls, current use of angiotensin II receptor blockers was followed by a decre

168 te this variation, 7 of 8 classes (excluding angiotensin II receptor blockers) had at least 1 widely

169 and chronic use of statins or ACE inhibitors/angiotensin II receptor blockers) or plasma concentratio

170 angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers), avoidance of potentia

171 rs (angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers).

172 Because angiotensin II receptor blockers, ACE inhibitors, and mi

173 Thiazide diuretics, angiotensin II receptor blockers, and ACE inhibitors may

174 rs, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, and mineralocorticoid

175 tunately, several modern drugs (eg, statins, angiotensin II receptor blockers, angiotensin-converting

176 titis, by degree of severity, among users of angiotensin II receptor blockers, as compared to non-use

177 s (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, aldoste

178 arge angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers, beta-blockers, and lip

179 of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, beta-blockers, and min

180 s (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, calcium

181 angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, beta-blockers, thiazid

182 and cardiovascular risk reduction-including angiotensin II receptor blockers, calcium channel blocke

183 e of angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers, lactates, renal replac

184 e collected from patients, with attention to angiotensin II receptor blockers, such as olmesartan, al

185 angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers--have been shown to be

186 AD2/3 and p38 signaling and was inhibited by angiotensin II receptor blockers.

187 mg/d) already receiving maximal therapy with angiotensin II receptor blockers.

188 ranged from 28% for beta-blockers to 65% for angiotensin II receptor blockers.

189 angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.

190 ngiotensin-converting enzyme) inhibitors and angiotensin II receptor blockers.

191 cal research suggests a protective effect of angiotensin II receptor blockers.

192 angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.

193 es (angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers/mineralocorticoid recep

194 The benefit of angiotensin II-receptor blockers (ARBs) in heart failure

195 eatment with TGF-beta antagonists, including angiotensin II-receptor blockers (ARBs).

196 ative risk, 0.65 [95% CI, 0.49 to 0.88]) and angiotensin II-receptor blockers (relative risk, 0.77 [C

197 but they support the clinical equivalence of angiotensin II-receptor blockers and ACE inhibitors in p

198 ectly compared the renoprotective effects of angiotensin II-receptor blockers and angiotensin-convert

199 The strength of evidence was rated high for angiotensin II-receptor blockers and statins, moderate f

200 angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers, and in patients with a

201 angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers.

202 in-converting enzyme inhibitors (ACEIs), and angiotensin-II receptor blockers (ARBs) have been increa

203 ensin-converting-enzyme (ACE) inhibitors and angiotensin-II receptor blockers (ARBs) have specific re

204 sonable to conclude that thiazide diuretics, angiotensin-II receptor blockers, and perhaps angiotensi

205 t they may not be as effective as diuretics, angiotensin-II receptor blockers, or ACE inhibitors; how

206 e ER and transport to the plasma membrane of angiotensin II receptors, but not adrenergic receptors.

207 ceiving regimens that stimulate type 2 and 4 angiotensin II receptors compared with 3.1 cases per 100

208 sive medications that stimulate type 2 and 4 angiotensin II receptors, compared with those that do no

209 ng neoplasia, we have examined the effect of angiotensin II receptor deficiency on 4-(methylnitrosami

210 nregulated collectrin expression in a type 1 angiotensin II receptor-dependent manner.

211 tein kinase C inhibitor Ro-31-8425, a mutant angiotensin II receptor (DRY/AAY), and a mutant angioten

212 The decrease of angiotensin II receptor expression may reflect the loss

213 tudied the effect of ischemia on hippocampal angiotensin II receptor expression, 1, 4 and 15 days aft

214 se in sodium transport, and up-regulation of angiotensin II receptor expression, of which expression

215 , such as antagonists of beta-adrenergic and angiotensin II receptors for heart failure and hypertens

216 binds several Galpha subunits immunoselected angiotensin II receptor-Galpha complexes.

217 tions that stimulate vs inhibit type 2 and 4 angiotensin II receptors had lower rates of incident cog

218 he availability of selective antagonists for angiotensin II receptors has focused interest on the gen

219 (AGT), and the type 1 (AT1) and type 2 (AT2) angiotensin II receptors, has been implicated in the pat

220 xpression of the AT1 and AT2 subtypes of the angiotensin II receptor in ventricular myocardium taken

221 n of renin-angiotensin system components and angiotensin II receptors in cardiac tissue suggests the

222 The number of angiotensin II receptors in normal liver was significant

223 the end of lactation had a higher density of angiotensin II receptors in the organum vasculosum lamin

224 ly, these effects were independent of type 1 angiotensin II receptor inhibition.

225 induced ER stress and inflammation, whereas angiotensin II receptor inhibitor, telmisartan reduced R

226 d the expression of RAS (angiotensinogen and angiotensin II receptor), insulin signaling, and autopha

227 edly reduced beta(2)-adrenergic receptor and angiotensin II receptor internalization and impaired act

228 Biased agonism of the angiotensin II receptor is known to promote cardiac cont

229 g-term beta-arrestin 2-biased agonism of the angiotensin II receptor may be a viable approach to the

230 f intact myofibrils, these data suggest that angiotensin II receptor-mediated activation of PKC may p

231 Type 1 angiotensin II receptor mRNA also approached a significa

232 In the dentate gyrus, angiotensin II receptor mRNA and angiotensin II binding

233 Type 1 angiotensin II receptor mRNA expression also correlated

234 Type 1 angiotensin II receptor mRNA expression at biopsy direct

235 Type 1 angiotensin II receptor mRNA expression significantly co

236 No changes in angiotensin II receptor mRNA or binding were detected 1

237 Angiotensin II receptor mRNA was found in the pyramidal

238 angiotensin II hepatoma may relate a loss of angiotensin II receptor on tumor neovasculature.

239 0067, a beta-arrestin 2-biased ligand of the angiotensin II receptor, or losartan, an angiotensin II

240 imens that stimulate or inhibit type 2 and 4 angiotensin II receptors, or mixed regimens (both stimul

241 use model of cerebral malaria, modulation of angiotensin II receptors produced similar effects, leadi

242 receptor expression may reflect the loss of angiotensin II receptor-producing neurons rather than a

243 d type, P = 7.8 x 10(-40)), which suppresses angiotensin II receptor signaling via allosteric transin

244 ingestion rather than from a destruction of angiotensin II receptor sites that directly provoke salt

245 tensin II infusion in hepatoma by evaluating angiotensin II receptor status in normal liver, hepatoma

246 The angiotensin II receptor status in the normal liver, hepa

247 trol mice, while the contractile response to angiotensin II receptor stimulation was unchanged.

248 These actions are mediated through angiotensin II receptors (subtype AT1), which activate t

249 s focused interest on the gene expression of angiotensin II-receptor subtypes in the human heart.

250 cation of Telmisartan (an antagonist for the angiotensin II receptor) through copper-mediated C-H ami

251 Patient sequence data revealed that angiotensin II receptor type 1 (AGTR1) is a shared targe

252 data analysis identified one important gene, angiotensin II receptor type 1 (AGTR1), in the Ca2+/AT-I

253 cient cells are sensitive to the blockade of angiotensin II receptor type 1 (Agtr1).

254 -2 binding, ACE2 downregulation enhances the angiotensin II receptor type 1 (AT(1) R) axis associated

255 Substantial evidence indicates that the angiotensin II receptor type 1 (AT1 R) is inherently mec

256 Intrarenal administration of angiotensin II receptor type 1 (AT1) receptor antagonist

257 tagonizes the classical angiotensin (Ang) II/angiotensin II receptor type 1 (AT1) receptor pathway.

258 n, and LOX-1 has been shown to interact with angiotensin II receptor type 1 (AT1).

259 al collection and identified telmisartan, an angiotensin II receptor type 1 (AT1R) blocker, as a pote

260 ay, we characterize a GPCR-TRP channel pair, angiotensin II receptor type 1 (AT1R), and transient rec

261 027, a beta-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), stimulates acute

262 it intracellular calcium release mediated by angiotensin II receptor type 1 (AT1R).

263 of blood pressure via angiotensin II and the angiotensin II receptor type 1 (AT1R).

264 r for advanced glycation end product [RAGE], angiotensin II receptor type 1 [AT(1)R]), p47(phox) NADP

265 This reduction makes angiotensin II receptor type 1 a promising therapeutic t

266 angiotensin-converting enzyme gene, and the angiotensin II receptor type 1 and receptor type 2 genes

267 giotensin II and substance P and through the angiotensin II receptor type 1 and substance P neurokini

268 An angiotensin II receptor type 1 antagonist inhibited mech

269 window of opportunity was tested by delaying angiotensin II receptor type 1 inhibition for 30 mins, 1

270 The results indicate that angiotensin II receptor type 1 plays a key role in the d

271 Inhibition of angiotensin II receptor type 1 significantly attenuated

272 Angiotensin II receptor type 1 was inhibited using cande

273 Blockage of angiotensin II receptor type 1 with 0.1 mg/kg candesarta

274 Inhibition of angiotensin II receptor type 1 with a delay of up to 4 h

275 renin, angiotensin I-converting enzyme, and angiotensin II receptor type 1) to interindividual varia

276 induced sympathoexcitation is independent of angiotensin II receptor type 1, oxytocin, ionotropic glu

277 AABs including autoantibody against angiotensin II receptor type 1/2, autoantibody against a

278 termed AT(1)-AAs, that bind and activate the angiotensin II receptor type 1a (AT(1) receptor).

279 T-PCR assays revealed the expression of both angiotensin II receptor type 1A (AT(1A)) and angiotensin

280 Expression of angiotensin II receptor type 1A decreased by 42% within

281 angiotensin II receptor type 1A (AT(1A)) and angiotensin II receptor type 1B (AT(1B)) subtypes in fre

282 KEY POINTS: The angiotensin II receptor type 1b (AT1 Rb ) is the primary

283 rs after controlled cortical impact, whereas angiotensin II receptor type 1B expression increased to

284 ), transforming growth factor beta (47%) and angiotensin II receptor type 2 (132%), 27% less elastin

285 In contrast, similar doses of the angiotensin II receptor type 2 (AT2) receptor ligand CGP

286 imal models suggest that in the vasculature, angiotensin II receptor type 2 (AT2-R) expression may be

287 Prevalent use of angiotensin II receptor type 2 and 4-stimulating or -inh

288 Angiotensin II receptor type I (AT(II)R(1)), induced by

289 myosin (CM), collagen V (Col V), agrin, and angiotensin II receptor type I (AT1).

290 ncreased ACE2 and MasR, as well as decreased angiotensin II receptor type I (AT1R) and angiotensin II

291 ed angiotensin II receptor type I (AT1R) and angiotensin II receptor type II (AT2R) expression levels

292 e reversed within minutes by pharmacological angiotensin-II receptor type 1 (AT1 R) blockade.

293 pathology and can be reversed acutely by an angiotensin-II receptor type 1 antagonist.

294 ngiotensin-I converting enzyme inhibitors or angiotensin-II receptor type 1 blockers may be less effe

295 ngiotensin-I converting enzyme inhibitors or angiotensin-II receptor type 1 blockers.

296 In addition, association of PKCalpha and angiotensin-II receptor, type 1, with Cav-3 was disrupte

297 he expression, localization and transport of Angiotensin II receptor types in the rat sciatic nerve p

298 In situ binding analysis revealed that angiotensin II receptors were mainly on the smooth muscl

299 Angiotensin II receptors were measured by saturation bin

300 Chronic (5 days) blockade of angiotensin II receptors with losartan elevated plasma r